ARVN: Arvinas Inc

ARVN新闻

• 13:08 Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
• 14:21 Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
• 14:19 KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
• 14:27 Reasons Why Investors Should Consider Betting on Arvinas Stock
• 13:47 TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
• 13:41 Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• 11:05 Arvinas表示，ARV-102在一项24名患者的1期帕金森病试验中显示出剂量依赖性的眼球运动改善，但该试验并非旨在评估疗效
• 20:02 Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders
• 11:03 Arvinas Announces First Patient Dosed In Phase 1/2 Trial Of ARV-6723 In Advanced Solid Tumors
• 11:25 Arvinas Q2 2026 Earnings Call Transcript
• 11:25 阿尔维纳斯2026年第二季度收益电话会议实录
• 16:31 Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
• 15:50 Can KT-621 Mark a Turning Point for Kymera Therapeutics?
• 13:58 Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN)
• 16:00 Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
• 02:10 Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL)
• 12:50 Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
• 15:18 Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
• 11:44 A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)
• 11:30 uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
• 12:25 Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
• 22:49 Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential (NASDAQ:GLUE)
• 17:54 These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Arvinas (NASDAQ:ARVN), Pfizer (NYSE
• 19:50 Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript